Open AccessDopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
Author(s) -
Wouter W. de Herder,
Ambroos E.M. Reijs,
Richard A. Feelders,
Maarten O. van Aken,
Eric P. Krenning,
H. L. J. Tanghe,
AartJan van der Lely,
Dik J. Kwekkeboom
Publication year - 2006
Publication title -
european journal of endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.897
H-Index - 148
eISSN - 1479-683X
pISSN - 0804-4643
DOI - 10.1530/eje.1.02281
Subject(s) - cabergoline , agonist , dopamine agonist , medicine , dopamine receptor d2 , endocrinology , dopamine , receptor , gastroenterology , urology , prolactin , hormone
Clinically non-functioning pituitary adenomas (NFPAs) can express functional dopamine D2 receptors. Therapy with dopamine (DA) agonists may result in a NFPA size reduction. However, DA agonist-sensitive and -resistant NFPAs are clinically indistinguishable. We have studied the correlation between in vivo imaging of D2 receptors using (123)I-epidepride and the radiological response of NFPA to DA in 18 patients.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom